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Abstract 
Background: Systemic inflammatory response in colorectal cancer (CRC) has been established as a prognostic factor 
for impaired cancer-specific survival, predominantly in patients with right-sided tumors. On the other hand, defective 
mismatch repair (dMMR) tumors, primarily located in the right colon, are known to have favorable survival and dense 
local immune infiltration. The aim of this study was to see if there is any form of relationship between these seemingly 
diverse entities.
Methods: Complete clinical and long-term survival data were retrieved for 316 CRC patients operated at Helsinki 
University Hospital between the years 1998 and 2003. Tissue microarrays were prepared from surgical specimens and 
further processed and analyzed for local immune cell infiltration using multispectral imaging with a Vectra quantita-
tive pathology imaging system and Inform software. Multiplex immunohistochemistry was applied using antibodies 
against CD66b, CD8, CD20, FoxP3, CD68 and pan-Cytokeratin. After exclusions, data on immune infiltration were avail-
able for 275 patients. Mismatch repair status was determined by immunohistochemistry.
Results: CRP was seen to be an independent predictor of cancer-specific survival but not overall survival in uni- and 
multivariable (HR 1.01 (1.00–1.02); p = 0.028) analyses of non-irradiated patients. There was no significant differ-
ence in CRP according to mismatch repair status, but all cases (n = 10) with CRP ≥ 75 mg/l had proficient mismatch 
repair (pMMR). There was a significant negative correlation between intratumor stromal infiltration by T-regulatory 
 FOXP3+ cells and CRP (p = 0.006). There was significantly lower intratumor stromal infiltration by  FOXP3+ cells 
(p = 0.043) in the right colon compared to the rectum, but no significant difference in CRP (p = 0.44). CRP was not a 
predictor of overall survival (HR 0.99, 95% CI 0.98–1.01) nor cancer-specific survival in irradiated patients (HR 0.94, 95% 
CI 0.94–1.02).
Conclusions: There was a significant negative relationship between SIR, defined as an elevated CRP, and intratumor 
stromal infiltration by T-regulatory  FOXP3+ cells. This and the fact that all cases with a CRP > 75 mg/l had pMMR sug-
gests that SIR and dMMR are independent entities in CRC. Indeed, the general lack of difference in CRP between cases 
with dMMR and pMMR may be evidence of overlap in cases with a less pronounced SIR.
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Background
Systemic inflammatory response (SIR), defined as ele-
vated circulating C-reactive protein (CRP), prior to colo-
rectal cancer (CRC) surgery has been established as an 
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independent risk factor for impaired survival [1, 2]. A sub-
sequent study further verified the relationship between 
SIR and impaired survival for patients with CRC liver 
metastases operated with curative intent [3]. In that study 
no relationship was seen between size of metastases and 
survival, indicating that immunological mechanisms and 
SIR are the detrimental factors rather than tumor burden 
per se. SIR is thus a factor that increases the mortality of 
a form of cancer that is the third most deadly malignant 
disease worldwide [4]. In the first study by our group [1], 
impaired survival associated with SIR was revealed stage 
for stage, and high CRP alone was seen to be a stronger 
predictor than the Glasgow prognostic scale [5] combin-
ing high CRP and low serum albumin. However, elevation 
of CRP in CRC can be due to several interfering factors. 
It may well be that an elevated CRP resulting from an 
inflammatory response, anemia and hypoalbuminemia 
has broader prognostic significance, whereas elevated 
CRP due to a tumor-induced SIR is a strong prognostic 
factor in a well-defined population only [6].
Previous studies have shown that most SIR-inducing 
CRCs are right-sided [1, 7]. The right colon is com-
monly regarded as the most immunoreactive section 
of the colo-rectum [8, 9]. Tumors with defective mis-
match repair (dMMR), which are also mainly located in 
the right colon, are seen to have strong local immune 
infiltration in the tumor microenvironment [10, 11]. 
Patients with dMMR tumors have a more favora-
ble oncologic survival than patients with tumors 
that induce an SIR, where cancer-specific survival is 
impaired [1, 2, 12, 13]. Thus, two forms of CRC with 
divergent immune responses and cancer-specific sur-
vival are predominantly located in the right colon. Little 
is known, however, about relationships or interference 
between SIR-inducing tumors and dMMR tumors.
No study has been published describing the under-
lying immunologic mechanism behind SIR induc-
tion in CRC, or the mechanism by which SIR impairs 
oncologic survival in CRC. Increase in our knowl-
edge of characteristics and local immune responses in 
SIR-inducing CRC tumors and their surroundings, is 
essential if we are to understand and possibly avert the 
detrimental processes associated with these tumors.
The aim of the present study was to compare local 
and systemic immune responses and MMR status with 
long-term outcome in a well-defined population of 
CRC patients, and how these interact to influence over-
all and cancer-specific survival.
The hypothesis of this study was that there is a rela-
tionship between tumor-induced SIR and tumors with 
dMMR in patients with right-sided CRC, and that there 
are common local tumor-associated immune events in 
these two entities.
Methods
This study comprised 316 CRC patients operated on at 
Helsinki University Hospital between 1998 and 2003. 
Data were extracted from patient records and tissue sam-
ples from the pathology archives of the hospital. The local 
research register included data on date of diagnosis, gen-
der, tumor location and stage of disease. CRP levels in 
preoperatively collected plasma samples, stored at -80 °C 
pending analysis, were obtained using a sensitive CRP 
assay at the local hospital laboratory [14]. Survival data 
and cause of death were gathered by matching the local 
research register with the Finnish Population Register 
and Statistics Finland. The mean and maximum follow-
up times were 7.3 and 17.1 years respectively.
Preparation for tissue microarrays
Marking of representative tumor areas was made on digi-
talized H&E slides by an experienced gastropathologist. 
The tissue microarray (TMA) blocks were generated by 
punching 1 mm cores from formalin-fixed and paraffin-
embedded tissue samples using a TMA Grand Master 3D 
instrument (Histech Ltd Budapest, Hungary). Two 1 mm 
cores were taken from each tumor area, one central and 
one peripheral to avoid systematic heterogeneity.
Multispectral imaging, analysis and data collection
Analysis of infiltrating immune cells using multiplexed 
immunohistochemistry and multispectral imaging 
has been described previously [15]. In brief, the TMA 
slides were sequentially stained with antibodies against 
CD66b, CD8, CD20, FoxP3, CD68 and pan-Cytokeratin. 
The VECTRA 3 Quantitative Pathology Imaging Sys-
tem (PerkinElmer) was used for multispectral imaging. 
All standard epi-flourescent filters were used; DAPI, 
FITC, CY3, Texas Red, and CY5. Whole slide scans were 
acquired using × 10 magnification. The Phenochart soft-
ware (PerkinElmer) was subsequently used to mark TMA 
cores from the whole slide scans for subsequent multi-
spectral imaging using x20 magnification. Images were 
quantified using the InForm software in two steps. Firstly, 
15 TMA cores representing the heterogeneous nature of 
CRC, were selected to train machine-learning algorithms 
for tissue segmentation, cell segmentation and cell phe-
notyping. These were then applied to all TMA cores. Each 
scanned image was examined by one observer under the 
supervision of an experienced gastropathologist.
Exclusion criteria and further processing of TMAs
TMA cores were excluded if one of the following crite-
ria was present: large part or whole of core lost; tumor 
or stromal tissue missing; poor quality staining (e.g. pan-
Cytokeratin stain too weak); or widespread necrosis. This 
resulted in final study samples from 275 patients. In 66 of 
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these, infiltration of immune cells was evaluated in one 
TMA core only.
TMA cores were checked for irrelevant areas that 
were manually indicated and subtracted from the image. 
Such areas included: cellular debris; mucus; large vessels; 
areas of necrosis, large lymphoid aggregates and normal 
epithelial tissue. After this exclusion process, cell seg-
mentation summary data were collected for each TMA 
core and converted to number of individual cell types 
per  mm2 (tumor or stromal compartment). The average 
number of a particular cell per  mm2 was calculated from 
the total number of cells divided by the total tissue area 
in cases where two TMA cores were included. Infiltrating 
immune cells, identified by the different markers, were 
further divided into groups of high and low infiltration by 
the median number of infiltrating cells.
Determination of mismatch repair status
MMR screening status was determined by immunohisto-
chemical analyses of TMA slides of the protein products 
of genes involved in the DNA mismatch repair system, as 
described previously [16]. Antibodies (all from Ventana 
Medical Systems Inc., Tucson, Arizona, US) against the 
four key mismatch repair proteins (MLH1 (clone M1), 
MSH2 (clone G219-1129), PMS2 (clone A16-4) and 
MSH6 (clone SP93)) were used on an automated Ventana 
BenchMark ULTRA instrument. Tumors with loss of 
nuclear expression of one or more of these proteins were 
described as dMMR, while samples with positive stain-
ing for all four antibodies were denoted pMMR. Tumors 
where internal staining was lacking, such as positive lym-
phocytes, were considered uninformative.
Statistical methods
Statistica® version 13 (StatSoft, Tulsa, OK, USA), 
STATA version 15.1 (STATACorp LLC, Texas, USA) 
and SPSS version 24 (IBM corp, Chicago, IL, USA) 
were used for statistical calculations. Non-parametric 
analyses were generally used. The Cox proportional 
hazard model was used for investigating associations 
between survival and predictor variables in uni- and 
multivariable analyses. CRP and age were included 
as continuous variables divided by 10. The assump-
tion of constant hazard ratio over time was tested by 
including time-dependent variables for each variable 
in the model. Interactions were also considered in the 
multivariable models, but no significant interactions 
were found when correcting for multiple comparisons 
using the Bonferroni method. The multivariable mod-
els were adjusted for age, gender, stage and location of 
the tumor. In cancer specific survival analyses other 
deaths were taken as competing events and compet-
ing cox regression models were used. Kaplan–Meier 
curves were used to analyze disease specific and over-
all survival. Differences in outcome between groups 
were analyzed using log-rank test.
Comparison of continuous data between groups was 
made with the Mann–Whitney U test. Correlation 
between continuous variables was evaluated using the 
Spearman’s rank test and bias corrected and accelerated 
95% confidence intervals for the Spearman’s rho were 
obtained by the bootstrap method (1000 replication). P 
values < 0.05 were considered statistically significant and 
two-tailed tests were used.
Irradiated patients were not included in the multivari-
able models. Possible effects of SIR were evaluated sepa-
rately in this group.
Ethics
Ethics approval was given by the Surgical Ethics Com-
mittee of Helsinki University Hospital (Dnro HUS 226/
E6/06, extension TMK02 §66 17.4.2013). The use of tis-
sue specimens was approved by The National Super-
visory Authority of Health and Welfare (Valvira Dnro 
10041/06).
Results
In all, 275 cases were included in the study. Basic charac-
teristics of the patients are shown in Table 1. Patients had 
a mean age of 67.9 years and distribution of gender was 
similar.
We found that CRP was a significant predictor of can-
cer-specific survival (Table 2a) in both the uni- and mul-
tivariable models but for overall survival (Table 2b) in the 
multivariable model only, after exclusion of irradiated 
patients. Localization of the tumor was not a predictor 
of overall nor cancer-specific survival in the univariable 
model. Age and stage were predictors of survival in both 
models. Overall and cancer specific survival accord-
ing to CRP and MMR status, stratified by infiltration of 
Table 1 Basic patient characteristics
Basic patient characteristic for the 275 patients included. Data are n (%) unless 
otherwise stated
Age years, mean (SD) 67.9 (12.2)
Female gender 132 (48%)
Stage I 55 (20%)
Stage II 77 (28%)
Stage III 95 (35%)
Stage IV 48 (17%)
Right colon 73 (27%)
Left colon 55 (20%)
Rectum non-irradiated 99 (36%)
Rectum irradiated 48 (17%)
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 FOXP3+ cells, are illustrated in Kaplan–Meier curves 
(Additional file 1 and Additional file 2).
Among irradiated rectal cancer patients, CRP (divided 
by ten) level was not a predictor of overall (HR 0.95, 95% 
CI 0.83–1.08) nor cancer-specific survival (HR 0.83, 95% 
CI 0.55–1.25).
Of the 275 cases analyzed for local infiltration of 
immune cells, it was possible to determine MMR status 
in 248 cases. Of these, 221 were pMMR and 27 (10.9%) 
dMMR tumors. When restricting the analysis to non-
irradiated patients as in the multivariable analyses, the 
corresponding figures were 183 and 26 (12.4%). There 
was no significant difference in CRP levels between 
dMMR and pMMR cases (median 4.9, IQR 1.7–15.6 
and median 3.1, IQR 1.7–16.4 for pMMR and dMMR, 
respectively, p = 0.785). However, all cases (n = 10) with 
a CRP > 75  g/l were pMMR. Neither when restricting 
analyses to the right colon, CRP level (median 6.6, IQR 
1.7–17.2 and median 3.0, IQR 1.6–17.4 for pMMR and 
dMMR, respectively, p = 0.693) was related to MMR 
status.
Infiltration of the tumor stroma by T-regulatory 
 FOXP3+ cells showed a significantly negative low correla-
tion to CRP (Spearman’s rho –0.18, 95% CI from –0.32 
to –0.05 for all non-irradiated and –0.24, 95% CI from 
–0.42 to –0.05 for non-irradiated rectal cancers (Table 3).
There was a negative but not significant relationship 
between CRP and tumor epithelial and tumor stromal 
infiltration of all other immune cells analyzed by the 
Vectra palette (Table  3). The correlation between CRP 
and infiltration of the intratumor stroma by T-regu-
latory  FOXP3+ cells was more pronounced in dMMR 
than pMMR cases (–0.53, 95% CI from –0.79 to –0.12; 
p = 0.006 and –0.18, 95% CI from –0.32 to –0.017; 
p = 0.014 respectively for non-irradiated patients). There 
was no significant correlation between dMMR and 
pMMR cases for any of the other infiltrating immune 
cells assessed (data not shown).
It should be mentioned that among non-irradiated 
patients there were several cases with a very low CRP 
level and low infiltration of  FOXP3+ cells in the intratu-
mor stroma despite the significant negative correlation 
(Fig. 1). Infiltration of intratumoral T-regulatory  FOXP3+ 
cells in the stroma correlated with local infiltration of all 
Table 2 Uni- and  multivariable analyses of  (a) cancer-
specific and (b) overall survival in non-irradiated CRCs
a CRP and age were included as continuous variables in steps of 10 units. The 
multivariable analysis was stratified for gender. Other deaths used as competing 
events
b CRP and age were included as continuous variables in steps of 10 units 
divided by 10. The multivariable analysis was stratified for gender and a time-
dependent correction term for age (1.10/year, 95% CI 1.03–1.17, p=0.004) was 
added to account for deviation from the Cox model assumption of constant 
hazard ratio over time
Variable Univariable Multivariable
HR (95%CI) p HR (95%CI) p
(a) Cancer  survivala
 Female 
gender
1.17 (0.74–1.83) 0.503
 Right colon 1.00 (Reference) 1.00 (Reference)
 Left colon 1.45 (0.77–2.71) 0.251 1.14 (0.60–2.17) 0.682
 Rectum 1.54 (0.88–2.70) 0.128 1.04 (0.58–1.89) 0.888
 Stage I 0.09 (0.02–0.37) 0.001 0.08 (0.02–0.33) < 0.001
 Stage II 0.34 (0.17–0.68) 0.002 0.25 (0.12–0.51) < 0.001
 Stage III 1.00 (Reference) 1.00 (Reference)
 Stage IV 3.08 (1.91–4.97) <0.001 3.43 (2.02–5.84) < 0.001
 CRP (per 
10mg/l)
1.09 (1.01–1.17) 0.022 1.08 (1.00–1.15) 0.042
 Age (per 10 
years)
1.24 (1.02–1.51) 0.032 1.59 (1.30–1.95) < 0.001
(b) Overall  survivalb
 Female 
gender
1.10 (0.78–1.54) 0.60
 Right colon 1.00 (Reference) 1.00 (Reference)
 Left colon 0.79 (0.49–1.28) 0.49 0.87 (0.52–1.44) 0.58
 Rectum 1.18 (0.80–1.73) 0.79 1.10 (0.73–1.64) 0.66
 Stage I 0.48 (0.28–0.81) 0.006 0.40 (0.23–0.70) 0.001
 Stage II 0.71 (0.46–1.10) 0.12 0.50 (0.32–0.80) 0.003
 Stage III 1.00 (Reference) 1.00 (Reference) Reference
 Stage IV 2.40 (1.53–3.76) < 0.001 3.13 (1.93–5.06) < 0.001
 CRP (per 
10mg/l)
1.05 (0.99–1.12) 0.096 1.08 (1.01–1.15) 0.037
 Age (per 10 
years)
2.00 (1.68–2.38) < 0.001 1.66 (1.25–2.20) < 0.001
Table 3 Correlation between CRP and immune cell infiltration
Spearman rank correlation between preoperative CRP and local infiltration by specific immune cell types (average cells/mm2)
N Stroma CD20 Stroma CD66b Stroma CD68 Stroma CD8 Stroma FOXP3 Tumor CD66b Tumor CD8
All non-irradi-
ated
227 −0.042 
(p = 0.52)
−0.085 
(p = 0.20)
−0.106 
(p = 0.11)
−0.013 
(p = 0.84)
−0.18 
(p = 0.006)
−0.087 
(p = 0.19)
−0.018 (p = 0.78)
Rectum non-
irradiated
99 −0.141 
(p = 0.16)
−0.131 
(p = 0.20)
−0.121 
(p = 0.23)
−0.001 
(p = 0.99)
−0.235 
(p = 0.019)
−0.144 
(p = 0.16)
−0.051 (p = 0.62)
Rectum irradi-
ated
48 0.116 (p = 0.43) −0.134 
(p = 0.36)
−0.275 
(p = 0.058)
−0.090 
(p = 0.54)
−0.163 
(p = 0.27)
0.137 (p = 0.35) −0.093 (p = 0.53)
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other investigated immune cells; p = 0.002 with stromal 
CD66b cells and p < 0.001 with the other immune cells.
In non-irradiated patients, intratumor stromal  FOXP3+ 
cell infiltration was greater in the right than in the left 
colon/rectum (67.5, IQR 14.3–197.4 and 29.1, IQR 5.9–
88.5 (cells/mm2) respectively, p = 0.044).
Discussion
An inverse relationship between systemic inflamma-
tory response (defined as elevated CRP) and infiltration 
of T-regulatory  FOXP3+ immune cells in the intratu-
mor stroma was seen in this well-defined cohort of CRC 
patients with long-term follow-up. To our knowledge, 
this is the first time local immune response in the tumor 
microenvironment has been compared to SIR in CRC. 
An inverse relationship was also seen with other immune 
cells but to a lower degree. The fact (Fig.  1) that there 
were several cases with low CRP and low  FOXP3+ cell 
infiltration indicate heterogeneity which may be depend-
ent on a third factor. This is congruent with the hypoth-
esized overlap between cases with dMMR and SIR, and 
this will be evaluated in further targeted studies.
In CRC patients, a high infiltration of  FOXP3+ cells has 
been linked to an improved prognosis [17, 18], which is 
in contrast to what has been shown for many other can-
cer types e.g. renal cancer and breast cancer [19]. Fur-
thermore, over the past decade SIR has been established 
as a strong negative prognostic factor [1, 2], which was 
also the case in the present study. The negative correla-
tion between tumor stromal infiltration by  FOXP3+ 
lymphocytes and SIR defined as elevated plasma CRP, 
as described in the present study, is congruent with that 
observation. However, a positive correlation between 
CRP level and  FOXP3+ cell tumor infiltration has been 
observed in clear cell renal cell carcinoma (RCC) [20]. 
The biological explanation for the suggested inverse rela-
tionship between CRP and  FOXP3+ cells in CRC remains 
speculative, and calls for further investigations. However, 
the strong positive correlation of  FOXP3+ cells to other 
infiltrating immune cells, including  CD8+ cytotoxic T 
cells, suggests that SIR is not likely to be the result of 
a strong local anti-tumor immune response in CRC. 
This emphasizes the fundamental differences that exist 
between different forms of cancer, and that the immune 
response may vary depending on both tumor- and organ-
specific factors. Mechanisms by which the FOXP3 com-
plex regulates infiltration of the tumor microenvironment 
by other immune cells at the molecular level are still not 
fully understood.  FOXP3+ T-regulatory cells are con-
sidered to play a key role in balancing different immune 
mechanisms and in maintaining immune homeostasis. It 
is thought that expression of specific genes interacts with 
the FOXP3 protein in T cells. For example, removal of 
the DBC1 gene in a breast cancer mouse model increased 
resistance to experimental autoimmune manifestations 
by attenuating FOXP3 degradation [20]. The present data 
do not identify any single precipitating factor for SIR in 
CRC but indicate that infiltration of  FOXP3+ T-regula-
tory cells may have an effect on cancer-specific survival.
In the present study, we found a fall in degree of infil-
tration of T-regulatory  FOXP3+ immune cells in the 
intratumor stroma of cancers from the right- to the left 
colon/rectum (excluding cases of irradiated rectum can-
cer). To our best knowledge this observation has not 
been published previously, but it is in accordance with 
the results of several tumor marker studies [8, 9], and 
with a recent study evaluating local lymphocyte infiltra-
tion in H&E slides [7]. The latter study [7] also found a 
corresponding fall in SIR that was not reproduced in the 
present study. Other studies have also described differ-
ences in the occurrence of SIR between cancers of the 
right and left colon [1, 2].
The proportion of dMMR cases in the present study 
was relatively small, and probably the result of a higher 
proportion of rectal cancers included due to the health-
care structure in the Helsinki region.
In contrast to the results of two studies [22, 23], CRP 
was not an independent predictor of survival among irra-
diated rectal cancer patients in this study. One reason for 
this may be that both previous studies analyzed patients 
after combined chemo-radiotherapy, while irradiated 
patients in the present study comprised patients receiv-
ing combined therapy and patients receiving short-term 
radiotherapy immediately followed by surgery. It may 
also be that the timing of CRP sampling some weeks after 
Fig. 1 Scatterplot of tumor stroma infiltration of  FOXP3+ T-regulatory 
cells versus CRP Infiltration T-regulatory  FOXP3+ immune cells in 
the tumor stroma (cells/mm2) plotted against CRP (mg/l) for pMMR 
(open circles) and dMMR (grey dots) patients. Linear regression lines 
with 95% CI plotted for pMMR (black lines) and dMMR (grey lines)
Page 6 of 8Gunnarsson et al. J Transl Med          (2020) 18:178 
chemo-radiotherapy reflects recovery and reorganization 
of the immune system in response to the chemotherapy, 
as described in cases of urine bladder cancer [24], which 
may potentiate its antitumoral effect.
No difference in CRP levels was seen between dMMR 
and pMMR tumors which supports our hypothesis that 
there is a relationship between these two entities. The 
observation that all cases with a CRP > 75  mg/l were 
pMMR tumors, however, suggests that cases with the 
most pronounced SIR were predominantly those with a 
systemic and not a local immune response. This agrees 
with the observed negative correlation between infil-
tration of  FOXP3+ T-regulatory cells in the intratumor 
stroma and CRP level (Table  3). The fact (Fig.  1) that 
there were several cases with low CRP and low  FOXP3+ 
cell infiltration indicate heterogeneity which may be 
dependent on a third factor. Interestingly this negative 
correlation was even more pronounced among dMMR 
cases, suggesting overlap and variation in the mix of 
immune responses underlying the homeostatic role of 
FOXP3 [21]. Furthermore, there was a significant posi-
tive correlation between tumor stromal infiltration by 
 FOXP3+ T-regulatory cells and local infiltration of the 
other immune cell types investigated. Thus, a lower 
degree of  FOXP3+cell infiltration was associated with 
a lower degree of infiltration of  CD8+ cytotoxic T-cells, 
although infiltration by  CD8+ cells was not statistically 
correlated to CRP.
When interpreting the regression plot in Fig. 1, all cases 
with a CRP higher than 75  mg/l were pMMR, whereas 
cases with lower CRP levels included both dMMR and 
pMMR tumors and no statistically significant difference 
was seen. The distribution of MMR status also served 
as a measurement of internal validity, since it is unlikely 
that other reasons for elevated CRP, such as autoimmune 
disease or infection, were missed when scrutinizing the 
records since all cases with the highest CRP had the same 
MMR status (pMMR).
As a measurement of external validity in the present 
study, CRP was verified as a predictor of cancer-specific 
survival but not of overall survival (Table 2a, b), which is 
in accordance with previously published data from our 
group [1] and the previously mentioned meta-analysis 
[2]. Several factors influence overall survival after surgery 
for CRC such as comorbidity and factors associated with 
higher age. Thus, the impact of SIR on cancer-specific 
survival observed in the present study speaks in favor of 
a true effect on the patient’s tumor characteristics. When 
analyzing a non-characterized crude population, other 
reasons for elevated CRP may attenuate the impact of 
SIR on the oncologic prognosis [6]. For this reason, the 
impact of SIR on survival seen in the present multivari-
able analysis necessitates a carefully controlled study 
population where reasons for elevated CRP levels other 
than SIR have been excluded.
A weakness of the present study is that it does not 
include cases where surgery was performed as an emer-
gency. A previous study showed impaired oncologic 
survival stage for stage in this group of patients but was 
unable to explain the reason for this [25]. It was hypoth-
esized that one reason could be differences in healthcare 
structure and emergency management, but a further 
study failed to verify this [26]. We suggest that immune 
mechanisms yet to be determined, both local immune 
infiltration and systemic immune responses to the tumor 
may well be key factors behind this phenomenon.
Another weakness is the use of TMAs and not whole 
tissue sections for the evaluation of local immune infil-
tration. The multispectral Vectra technique work flow is 
primarily designed for TMAs and not for whole tissue 
sections. To minimize the risk of influences from system-
atic intratumoral heterogeneity, tumour immune infiltra-
tion was evaluated from two individual TMA cores from 
within the tumor mass, one more central and one more 
peripheral. The novel multispectral Vectra technique 
adds complex information of local immune cell infiltra-
tion and the relation to SIR, however, the findings need 
to be validated in future studies.
Conclusions
In conclusion there was a significant negative relationship 
between SIR defined as an elevated CRP and infiltration 
of T-regulatory  FOXP3+ cells in the intratumor stroma. 
This, and the fact that all cases with a CRP > 75 mg/l were 
pMMR tumors suggests that SIR and dMMR are two 
separate entities. On the other hand, the absence of an 
overall difference in CRP between dMMR and pMMR 
tumors favors an overlap in cases with less pronounced 
SIR. Thus, our hypothesis of a partial overlap holds true 
when restricted to cases with lower degrees of SIR.
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